– USA, NY – OS Therapies (NYSE-A: OSTX), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, announced the appointments of Avril McKean Dieser and Olivier Jarry to its Board as Independent Directors, bringing over 50 years of biopharmaceutical executive decision-making experience to the Company, with a specific focus in commercializing biologic products.
About Avril McKean Dieser
Avril McKean Dieser holds a global role as VP of Head of Legal Patient Evidence of UCB, Inc., a subsidiary of UCB, S.A., a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or the central nervous system. At UCB, she leads a team of attorneys supporting UCB’s global assets, global payer functions, and regulatory, medical, and patient communities, including clinical development. Ms. McKean Dieser was formerly a member of the AbbVie Inc. legal team providing global product support for the immunology and oncology franchises and was the government pricing lawyer for all pharmaceutical and combination products from May 2013 to July 2016. Before joining the pharmaceutical industry, Ms. McKean Dieser practiced corporate law in Atlanta, Georgia at two nationally recognized law firms. She earned her J.D. degree from The Catholic University Columbus School of Law and is admitted to practice law in the states of Georgia and Illinois. Before receiving her law degree, Ms. McKean Dieser received an M.A. in Public Administration from the University of Maryland, European Division, and a B.A. degree in English Literature from Duquesne University. Ms. McKean Dieser lost her son, Edward, to Osteosarcoma in January 2024 at the age of 21.
“I am deeply grateful that OS Therapies’ mission is to bring to market the first new osteosarcoma treatment in over 40 years,” said Ms. McKean Dieser. “As a newly appointed director, I will focus on helping management implement its regulatory and commercialization plan so that OST-HER2 can ultimately reach the patients and families desperate for new solutions in this very hard to treat childhood cancer.”
About Olivier R. Jarry
Olivier Jarry is the Co-founder and CEO of Libera Bio S.L., a private Spanish biopharmaceutical company devoted to the development of a new class of precision therapeutics to address intracellular cancer targets. He also serves as COO of Advantage Therapeutics Inc., an investigational-stage company focused on the diseases of aging, and as CFO of Rational Vaccines, Inc., an investigational-stage infectious disease company. Olivier Jarry served as President and CCO of DarioHealth (Nasdaq: DRIO) from October 2017 until January 2020. Between 2015 and 2016, he served as SVP of the Consumer Sector and Officer at Intrexon Corp. (NYSE: XON), a biotechnology company focused on engineering biological systems to enable DNA-based control over the function and output of living cells. Before Intrexon, from 2011 to 2012, Mr. Jarry served as the Head of Strategy, Operation, and Market Access, focusing on Emerging Markets, for Bristol-Myers Squibb (NYSE: BMY), where he oversaw the product launch and growth of innovative medicines relating to oncology, virology, rheumatology, cardiovascular and diabetes. Before that, he served as the Global Business Unit Head of Bayer Diabetes Care, a division of Bayer HealthCare Pharmaceuticals LLC, and in several leadership roles at Novartis International AG (NYSE: NVS).
“OS Therapies represents a unique opportunity to bring to market a novel cancer immunotherapy in the rare pediatric disease of osteosarcoma that could thereafter potentially change the standard of care in HER2 expressing cancers given its novel mechanism of action,” said Olivier Jarry, newly appointed independent Board member of OS Therapies. “The potential to receive a priority review voucher following approval in osteosarcoma that could then be sold to help fund the commercialization of OST-HER2 in osteosarcoma and potential label-expanding clinical trials into breast cancer, colorectal cancer and/or other solid tumors is compelling from both an investment and product development perspective. I am excited to help play an important role in supporting the Company to achieve its strategic objectives.”
Olivier Jarry holds an M.Sc. degree from Ecole Centrale de Pari and an MEng.Degree from Délégation Générale pour l’Armement, and a Trium Executive MBA degree jointly awarded by NYU Stern School of Business, London School of Economics and Political Science, and Hautes Études Commerciales Paris.
About OS Therapies
OS Therapies is a clinical-stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company’s lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. The Company has completed enrollment for a 41-patient Phase 2b clinical trial of OST-HER2 in resected, recurrent osteosarcoma, with results expected in the fourth quarter of 2024. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing strong preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma. In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) platform, known as tunable ADC, which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company’s proprietary silicone linker technology, enabling the delivery of multiple payloads per linker.
For more information: https://www.ostherapies.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.